Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study

Emilio Iannitto, Monica Bellei, Sandy Amorim, Andrés J.M. Ferreri, Luigi Marcheselli, Marina Cesaretti, Corinne Haioun, Salvatrice Mancuso, Krimo Bouabdallah, Remy Gressin, Claudio Tripodo, Alexandra Traverse-Glehen, Lucile Baseggio, Simonetta Zupo, Caterina Stelitano, Barbara Castagnari, Caterina Patti, Isabel Alvarez, Anna Marina Liberati, Michele MerliGuido Gini, Maria Giuseppina Cabras, Jean Dupuis, Benoit Tessoulin, Aurore Perrot, Francesca Re, Francesca Palombi, Alessandro Gulino, Emanuele Zucca, Massimo Federico, Catherine Thieblemont

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Splenectomy in addition to immunotherapy with rituximab can provide quick and sometimes durable disease control in patients with splenic marginal zone lymphoma (SMZL). However, systemic chemotherapy is ultimately required in many cases. The BRISMA (Bendamustine-rituximab as first-line treatment of splenic marginal zone lymphoma)/IELSG (International Extranodal Lymphoma Study Group)36 trial is an open-label, single arm phase II study designed by the IELSG in cooperation with the Fondazione Italiana Linfomi and the lymphoma Study Association according to Simon's two-stage method. The primary endpoint was complete response rate. Fifty-six patients with SMZL diagnosis confirmed on central revision were treated with bendamustine (90 mg/m2 days 1, 2) and rituximab (375 mg/m2 day 1) every 28 days for six cycles (B-R). The overall response and CR rates were 91% and 73%, respectively. Duration of response, progression-free survival and overall survival at 3 years were 93% (95% confidence interval [CI] 81–98), 90% (95% CI 77–96) and 96% (95% CI 84–98), respectively. Toxicity was mostly haematological. Neutropenia grade ≥3 was recorded in 43% of patients; infections and febrile neutropenia in 5·4% and 3·6%. Overall, 14 patients (25%) experienced serious adverse events. Five patients (9%) went off-study because of toxicity and one patient died from infection. In conclusion, B-R resulted in a very effective first-line regimen for SMZL. Based on the results achieved in the BRISMA trial, B-R should be considered when a chemotherapy combination with rituximab is deemed necessary for symptomatic SMZL patients.

Original languageEnglish
Pages (from-to)755-765
Number of pages11
JournalBritish Journal of Haematology
Volume183
Issue number5
DOIs
Publication statusPublished - 2018

Fingerprint

Lymphoma
Confidence Intervals
Febrile Neutropenia
Splenectomy
Infection
Bendamustine Hydrochloride
Rituximab
Combination Drug Therapy
Neutropenia
Immunotherapy
Disease-Free Survival
Drug Therapy
Survival

Keywords

  • bendamustine
  • first-line therapy
  • immunochemotherapy
  • rituximab
  • Splenic Marginal Zone Lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma : results from the phase II BRISMA/IELSG36 study. / Iannitto, Emilio; Bellei, Monica; Amorim, Sandy; Ferreri, Andrés J.M.; Marcheselli, Luigi; Cesaretti, Marina; Haioun, Corinne; Mancuso, Salvatrice; Bouabdallah, Krimo; Gressin, Remy; Tripodo, Claudio; Traverse-Glehen, Alexandra; Baseggio, Lucile; Zupo, Simonetta; Stelitano, Caterina; Castagnari, Barbara; Patti, Caterina; Alvarez, Isabel; Liberati, Anna Marina; Merli, Michele; Gini, Guido; Cabras, Maria Giuseppina; Dupuis, Jean; Tessoulin, Benoit; Perrot, Aurore; Re, Francesca; Palombi, Francesca; Gulino, Alessandro; Zucca, Emanuele; Federico, Massimo; Thieblemont, Catherine.

In: British Journal of Haematology, Vol. 183, No. 5, 2018, p. 755-765.

Research output: Contribution to journalArticle

Iannitto, E, Bellei, M, Amorim, S, Ferreri, AJM, Marcheselli, L, Cesaretti, M, Haioun, C, Mancuso, S, Bouabdallah, K, Gressin, R, Tripodo, C, Traverse-Glehen, A, Baseggio, L, Zupo, S, Stelitano, C, Castagnari, B, Patti, C, Alvarez, I, Liberati, AM, Merli, M, Gini, G, Cabras, MG, Dupuis, J, Tessoulin, B, Perrot, A, Re, F, Palombi, F, Gulino, A, Zucca, E, Federico, M & Thieblemont, C 2018, 'Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study', British Journal of Haematology, vol. 183, no. 5, pp. 755-765. https://doi.org/10.1111/bjh.15641
Iannitto, Emilio ; Bellei, Monica ; Amorim, Sandy ; Ferreri, Andrés J.M. ; Marcheselli, Luigi ; Cesaretti, Marina ; Haioun, Corinne ; Mancuso, Salvatrice ; Bouabdallah, Krimo ; Gressin, Remy ; Tripodo, Claudio ; Traverse-Glehen, Alexandra ; Baseggio, Lucile ; Zupo, Simonetta ; Stelitano, Caterina ; Castagnari, Barbara ; Patti, Caterina ; Alvarez, Isabel ; Liberati, Anna Marina ; Merli, Michele ; Gini, Guido ; Cabras, Maria Giuseppina ; Dupuis, Jean ; Tessoulin, Benoit ; Perrot, Aurore ; Re, Francesca ; Palombi, Francesca ; Gulino, Alessandro ; Zucca, Emanuele ; Federico, Massimo ; Thieblemont, Catherine. / Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma : results from the phase II BRISMA/IELSG36 study. In: British Journal of Haematology. 2018 ; Vol. 183, No. 5. pp. 755-765.
@article{95858dabb13c44089d318819a6d92b0f,
title = "Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study",
abstract = "Splenectomy in addition to immunotherapy with rituximab can provide quick and sometimes durable disease control in patients with splenic marginal zone lymphoma (SMZL). However, systemic chemotherapy is ultimately required in many cases. The BRISMA (Bendamustine-rituximab as first-line treatment of splenic marginal zone lymphoma)/IELSG (International Extranodal Lymphoma Study Group)36 trial is an open-label, single arm phase II study designed by the IELSG in cooperation with the Fondazione Italiana Linfomi and the lymphoma Study Association according to Simon's two-stage method. The primary endpoint was complete response rate. Fifty-six patients with SMZL diagnosis confirmed on central revision were treated with bendamustine (90 mg/m2 days 1, 2) and rituximab (375 mg/m2 day 1) every 28 days for six cycles (B-R). The overall response and CR rates were 91{\%} and 73{\%}, respectively. Duration of response, progression-free survival and overall survival at 3 years were 93{\%} (95{\%} confidence interval [CI] 81–98), 90{\%} (95{\%} CI 77–96) and 96{\%} (95{\%} CI 84–98), respectively. Toxicity was mostly haematological. Neutropenia grade ≥3 was recorded in 43{\%} of patients; infections and febrile neutropenia in 5·4{\%} and 3·6{\%}. Overall, 14 patients (25{\%}) experienced serious adverse events. Five patients (9{\%}) went off-study because of toxicity and one patient died from infection. In conclusion, B-R resulted in a very effective first-line regimen for SMZL. Based on the results achieved in the BRISMA trial, B-R should be considered when a chemotherapy combination with rituximab is deemed necessary for symptomatic SMZL patients.",
keywords = "bendamustine, first-line therapy, immunochemotherapy, rituximab, Splenic Marginal Zone Lymphoma",
author = "Emilio Iannitto and Monica Bellei and Sandy Amorim and Ferreri, {Andr{\'e}s J.M.} and Luigi Marcheselli and Marina Cesaretti and Corinne Haioun and Salvatrice Mancuso and Krimo Bouabdallah and Remy Gressin and Claudio Tripodo and Alexandra Traverse-Glehen and Lucile Baseggio and Simonetta Zupo and Caterina Stelitano and Barbara Castagnari and Caterina Patti and Isabel Alvarez and Liberati, {Anna Marina} and Michele Merli and Guido Gini and Cabras, {Maria Giuseppina} and Jean Dupuis and Benoit Tessoulin and Aurore Perrot and Francesca Re and Francesca Palombi and Alessandro Gulino and Emanuele Zucca and Massimo Federico and Catherine Thieblemont",
year = "2018",
doi = "10.1111/bjh.15641",
language = "English",
volume = "183",
pages = "755--765",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "5",

}

TY - JOUR

T1 - Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma

T2 - results from the phase II BRISMA/IELSG36 study

AU - Iannitto, Emilio

AU - Bellei, Monica

AU - Amorim, Sandy

AU - Ferreri, Andrés J.M.

AU - Marcheselli, Luigi

AU - Cesaretti, Marina

AU - Haioun, Corinne

AU - Mancuso, Salvatrice

AU - Bouabdallah, Krimo

AU - Gressin, Remy

AU - Tripodo, Claudio

AU - Traverse-Glehen, Alexandra

AU - Baseggio, Lucile

AU - Zupo, Simonetta

AU - Stelitano, Caterina

AU - Castagnari, Barbara

AU - Patti, Caterina

AU - Alvarez, Isabel

AU - Liberati, Anna Marina

AU - Merli, Michele

AU - Gini, Guido

AU - Cabras, Maria Giuseppina

AU - Dupuis, Jean

AU - Tessoulin, Benoit

AU - Perrot, Aurore

AU - Re, Francesca

AU - Palombi, Francesca

AU - Gulino, Alessandro

AU - Zucca, Emanuele

AU - Federico, Massimo

AU - Thieblemont, Catherine

PY - 2018

Y1 - 2018

N2 - Splenectomy in addition to immunotherapy with rituximab can provide quick and sometimes durable disease control in patients with splenic marginal zone lymphoma (SMZL). However, systemic chemotherapy is ultimately required in many cases. The BRISMA (Bendamustine-rituximab as first-line treatment of splenic marginal zone lymphoma)/IELSG (International Extranodal Lymphoma Study Group)36 trial is an open-label, single arm phase II study designed by the IELSG in cooperation with the Fondazione Italiana Linfomi and the lymphoma Study Association according to Simon's two-stage method. The primary endpoint was complete response rate. Fifty-six patients with SMZL diagnosis confirmed on central revision were treated with bendamustine (90 mg/m2 days 1, 2) and rituximab (375 mg/m2 day 1) every 28 days for six cycles (B-R). The overall response and CR rates were 91% and 73%, respectively. Duration of response, progression-free survival and overall survival at 3 years were 93% (95% confidence interval [CI] 81–98), 90% (95% CI 77–96) and 96% (95% CI 84–98), respectively. Toxicity was mostly haematological. Neutropenia grade ≥3 was recorded in 43% of patients; infections and febrile neutropenia in 5·4% and 3·6%. Overall, 14 patients (25%) experienced serious adverse events. Five patients (9%) went off-study because of toxicity and one patient died from infection. In conclusion, B-R resulted in a very effective first-line regimen for SMZL. Based on the results achieved in the BRISMA trial, B-R should be considered when a chemotherapy combination with rituximab is deemed necessary for symptomatic SMZL patients.

AB - Splenectomy in addition to immunotherapy with rituximab can provide quick and sometimes durable disease control in patients with splenic marginal zone lymphoma (SMZL). However, systemic chemotherapy is ultimately required in many cases. The BRISMA (Bendamustine-rituximab as first-line treatment of splenic marginal zone lymphoma)/IELSG (International Extranodal Lymphoma Study Group)36 trial is an open-label, single arm phase II study designed by the IELSG in cooperation with the Fondazione Italiana Linfomi and the lymphoma Study Association according to Simon's two-stage method. The primary endpoint was complete response rate. Fifty-six patients with SMZL diagnosis confirmed on central revision were treated with bendamustine (90 mg/m2 days 1, 2) and rituximab (375 mg/m2 day 1) every 28 days for six cycles (B-R). The overall response and CR rates were 91% and 73%, respectively. Duration of response, progression-free survival and overall survival at 3 years were 93% (95% confidence interval [CI] 81–98), 90% (95% CI 77–96) and 96% (95% CI 84–98), respectively. Toxicity was mostly haematological. Neutropenia grade ≥3 was recorded in 43% of patients; infections and febrile neutropenia in 5·4% and 3·6%. Overall, 14 patients (25%) experienced serious adverse events. Five patients (9%) went off-study because of toxicity and one patient died from infection. In conclusion, B-R resulted in a very effective first-line regimen for SMZL. Based on the results achieved in the BRISMA trial, B-R should be considered when a chemotherapy combination with rituximab is deemed necessary for symptomatic SMZL patients.

KW - bendamustine

KW - first-line therapy

KW - immunochemotherapy

KW - rituximab

KW - Splenic Marginal Zone Lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85056177075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056177075&partnerID=8YFLogxK

U2 - 10.1111/bjh.15641

DO - 10.1111/bjh.15641

M3 - Article

AN - SCOPUS:85056177075

VL - 183

SP - 755

EP - 765

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -